Top Indian drugmakers say they need stricter compliance procedures and greater investment in quality to maintain their share in the global market amid concerns about increasing global enforcements. "Domestic companies represent a significant part of the global drug industry and, therefore, there is an increase in the scrutiny of these companies," Biocon Chairman and Managing Director Kiran Mazumdar-Shaw said. Audits are more frequent than earlier periodic reviews because of the U.S. FDA's presence in the country now, she said.

Related Summaries